サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1765373

がん悪液質の世界市場

Cancer Cachexia

出版日
ページ情報
英文 255 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
がん悪液質の世界市場
出版日: 2025年07月09日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 255 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

がん悪液質の世界市場は2030年までに37億米ドルに到達

2024年に27億米ドルと推定されるがん悪液質の世界市場は、分析期間2024-2030年にCAGR 5.7%で成長し、2030年には37億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである黄体ホルモンは、CAGR 5.9％を記録し、分析期間終了時には15億米ドルに達すると予想されます。副腎皮質ステロイド分野の成長率は、分析期間中CAGR 5.1％と推定されます。

米国市場は9億8,550万米ドルと推定、中国はCAGR 7.6％で成長予測

米国のがん悪液質市場は、2024年には9億8,550万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに3億1,400万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.4%と4.8%と予測されています。欧州では、ドイツがCAGR 5.4%で成長すると予測されています。

世界のがん悪液質市場- 主要動向と促進要因まとめ

がん悪液質は、重度の体重減少、筋力低下、食欲不振を特徴とする多因子症候群であり、がん患者のQOLと生存率に大きな影響を与えます。一般的な栄養不良とは異なり、がん悪液質は腫瘍とそれに対する身体の反応に関連した複雑な代謝変化と炎症によって引き起こされます。この症候群は、タンパク質とエネルギーのバランスがマイナスになり、従来の栄養サポートではなかなか元に戻りません。がん悪液質治療薬は、がん患者における深刻な体重減少、筋萎縮、食欲不振を特徴とする、複雑で衰弱したがん悪液質症候群に対処することに焦点を当てています。この症状は、患者のQOL、治療効果、全体的な予後に大きな影響を与えます。一般的な栄養不良とは異なり、がん悪液質は全身性の炎症、代謝異常、ホルモン変化などの複合的な要因によって引き起こされ、タンパク質とエネルギーのバランスがマイナスになります。従来の栄養補給だけでは不十分であり、標的治療薬の開発が必要です。がん悪液質治療薬における現在のアプローチには、抗炎症剤、食欲増進剤、蛋白同化ステロイド、代謝経路を調節して筋肉量を維持し、患者の転帰を改善する薬剤などがあります。

がん悪液質の基礎となるメカニズムの解明が進み、いくつかの有望な治療標的が同定されました。例えば、TNF-αやIL-6のような炎症性サイトカインを標的とする薬剤は、全身の炎症を抑える可能性があるとして研究されています。さらに、グレリン作動薬やその他の食欲増進薬は、食欲不振に対抗し、カロリー摂取を改善することを目的としています。選択的アンドロゲン受容体モジュレーター（SARM）のような同化作用のある薬剤は、筋タンパク質の合成を促進し、筋肉の消耗を防ぐために研究されています。さらに、悪液質の複数の側面に同時に対処する併用療法が開発中であり、治療により包括的なアプローチを提供しています。これらの進歩は、この多因子性症候群と効果的に闘うための多面的戦略の必要性が認識されつつあることを反映しています。

がん悪液質治療薬市場の成長は、がんの有病率の上昇、この疾患に対する認識の高まり、治療研究の進行など、いくつかの要因によって牽引されています。がん患者の世界の増加は、当然ながら悪液質の発生率の上昇につながり、効果的な治療に対する緊急の必要性を浮き彫りにしています。医療従事者や患者の間で、悪液質ががんの治療成績に与える影響が大きいという認識が高まり、専門的な治療薬に対する需要が高まっています。継続的な研究開発努力により新たな治療薬の候補が生まれ、既存の治療薬も最適化され、市場の成長をさらに後押ししています。さらに、がん研究に対する政府の支援政策と資金援助が、新規治療法の開発と承認を促進しています。個々の患者の遺伝的・代謝的プロファイルに合わせた治療を行う個別化医療へのシフトも、より的を絞った効果的な悪液質治療の採用を促進すると予想されます。全体として、悪液質治療薬市場は、新たな治療法の出現と既存治療法の改良により、この困難な病態によりよく対処できるようになるため、大幅な拡大が見込まれています。

セグメント

治療薬（黄体ホルモン、副腎皮質ホルモン、併用療法、その他の治療薬）、エンドユーザー（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例

  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • Charles River Laboratories International, Inc.
  • Aphios Corporation
  • Fresenius SE & Co. KGaA
  • AbbVie, Inc.
  • AVEO Pharmaceuticals, Inc.
  • AAVogen, Inc.
  • Immuneering
  • Caelus Health
  • AliveGen USA
  • Endevica Bio
  • Extend Biosciences

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • NSAID
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP16251

Global Cancer Cachexia Market to Reach US$3.7 Billion by 2030

The global market for Cancer Cachexia estimated at US$2.7 Billion in the year 2024, is expected to reach US$3.7 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. Progestogens, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Corticosteroids segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$985.5 Million While China is Forecast to Grow at 7.6% CAGR

The Cancer Cachexia market in the U.S. is estimated at US$985.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$314.0 Million by the year 2030 trailing a CAGR of 7.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.4% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

Global Cancer Cachexia Market - Key Trends & Drivers Summarized

Cancer cachexia is a multifactorial syndrome characterized by severe body weight loss, muscle wasting, and anorexia, significantly impacting the quality of life and survival rates of cancer patients. Unlike general malnutrition, cancer cachexia is driven by complex metabolic changes and inflammation associated with the tumor and the body's response to it. This syndrome leads to a negative protein and energy balance, which is not easily reversed by conventional nutritional support. Cancer cachexia therapeutics are focused on addressing the complex and debilitating syndrome of cancer cachexia, characterized by severe weight loss, muscle atrophy, and anorexia in cancer patients. This condition significantly impacts patient quality of life, treatment efficacy, and overall prognosis. Unlike general malnutrition, cancer cachexia is driven by a combination of factors including systemic inflammation, metabolic dysregulation, and hormonal changes that lead to a negative protein and energy balance. Traditional nutritional support alone is insufficient, necessitating the development of targeted therapeutics. Current approaches in cancer cachexia therapeutics include anti-inflammatory agents, appetite stimulants, anabolic steroids, and agents that modulate metabolic pathways to preserve muscle mass and improve patient outcomes.

Advancements in the understanding of cancer cachexia's underlying mechanisms have led to the identification of several promising therapeutic targets. For instance, drugs targeting pro-inflammatory cytokines such as TNF-alpha and IL-6 are being investigated for their potential to reduce systemic inflammation. Additionally, ghrelin agonists and other appetite stimulants aim to counteract anorexia and improve caloric intake. Anabolic agents such as selective androgen receptor modulators (SARMs) are being explored to promote muscle protein synthesis and prevent muscle wasting. Furthermore, combination therapies that address multiple aspects of cachexia simultaneously are under development, offering a more comprehensive approach to treatment. These advancements reflect a growing recognition of the need for multifaceted strategies to effectively combat this multifactorial syndrome.

The growth in the cancer cachexia therapeutics market is driven by several factors, including the rising prevalence of cancer, increased awareness of the condition, and ongoing advancements in therapeutic research. The global increase in cancer cases naturally leads to a higher incidence of cachexia, highlighting the urgent need for effective treatments. Greater awareness among healthcare providers and patients about the significant impact of cachexia on cancer treatment outcomes has spurred demand for specialized therapeutics. Continuous research and development efforts are yielding new therapeutic candidates and optimizing existing ones, further propelling market growth. Additionally, supportive government policies and funding for cancer research are facilitating the development and approval of novel treatments. The shift towards personalized medicine, with therapies tailored to individual patients' genetic and metabolic profiles, is also expected to drive the adoption of more targeted and effective cachexia treatments. Overall, the cancer cachexia therapeutics market is poised for significant expansion as new therapies emerge and existing ones are refined to better address this challenging condition.

SCOPE OF STUDY:

The report analyzes the Cancer Cachexia market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapeutics (Progestogens, Corticosteroids, Combination Therapies, Other Therapeutics); End-Use (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 50 Featured) -

  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • Charles River Laboratories International, Inc.
  • Aphios Corporation
  • Fresenius SE & Co. KGaA
  • AbbVie, Inc.
  • AVEO Pharmaceuticals, Inc.
  • AAVogen, Inc.
  • Immuneering
  • Caelus Health
  • AliveGen USA
  • Endevica Bio
  • Extend Biosciences

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Cancer: An Insight
    • A Prelude to Cancer Cachexia
    • Cachexia Treatment
    • Pharmacologic Approaches for Clinical Management of Cancer Cachexia
    • Cancer Cachexia Market Faces a Challenge Amid the Pandemic
    • Percentage YoY Change in Sales of Select Physician-Administered Oncology Products Chemotherapy Administration: (March-June) 2019 Vs 2020March
    • Pandemic Impact on Cancer Research
    • Tariff Impact on Global Supply Chain Patterns
    • Cancer Cachexia - Global Key Competitors Percentage Market Share in 2025 (E)
    • Global Market Prospects and Outlook
    • Progestogens Account for a Major Share, Combination Therapies to Drive Growth
    • North America and Europe Constitute Major Regions, Asia-Pacific Exhibits the Fastest Growth
    • Competition
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Recent Market Activity
    • Market Challenges
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rise in Number of Cancer Cases, and High Prevalence of Cancer Cachexia to Drive Market Growth
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Numerous Efforts Underway to Improve Therapy for Cancer Presents Lucrative Opportunities
    • Promising Treatment Options Drive Market Gains
  • NSAID
    • Erythropoietin
    • IL-1a, IL-6 & TNFa Inhibitors
    • Myostatin Inhibitors
    • Appetite & Metabolism Modulators
    • Cytokine Modulator
    • Anabolic Agents
    • Combination Therapies
    • DNA Link to throw More Light on Cancer Cachexia
    • Ageing Demographics to Drive Market Demand
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Cancer Research Spending Continues to Witness Growth
    • Pipeline Analysis
    • Macimorelin from AEterna Zentaris
    • PF- 06946860 from Pfizer
    • TCMCB07 from Endevica Bio
    • Actimed Therapeutics S-pindolol
    • Lenalidomide
    • AV-380
    • Select Unimodal Treatment Agents for Cancer Cachexia Currently Under Clinical Trial
    • Combination of Medical Therapeutics and Nutritional Interventions to Provide Better Outcome
    • Select Key Developments
    • Helsinn Launches Adlumiz for Cancer Cachexia Patients in Japan
    • Researchers Secure Program Project Grant to Uncover Biology behind Cancer Cachexia
    • Researchers Secure Program Project Grant to Uncover Biology behind Cancer Cachexia
    • Researchers Develop New Drug with Potential to Improve & Treat Cancer Cachexia
    • Actimed Therapeutics Plans to Advance Lead Compound for Cancer Cachexia
    • Actimed Therapeutics Plans to Advance Lead Compound for Cancer Cachexia
    • ESMO Publishes New Guidelines on Cachexia Management in Adult Cancer Patients
    • Uptrend in Healthcare Spending Drives Market Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cancer Cachexia Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cancer Cachexia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cancer Cachexia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Cancer Cachexia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Progestogens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Progestogens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Progestogens by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Combination Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Combination Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Combination Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Market Facts & Figures
    • US Cancer Cachexia Market Share (in %) by Company: 2022 & 2030
    • Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • JAPAN
    • Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • CHINA
    • Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • EUROPE
    • Market Facts & Figures
    • European Cancer Cachexia Market: Competitor Market Share Scenario (in %) for 2022 & 2030
    • Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Cancer Cachexia by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Cancer Cachexia by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Cancer Cachexia by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • FRANCE
    • Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • GERMANY
    • Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Rest of Europe 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Asia-Pacific 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of World 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of World 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030

IV. COMPETITION